| Literature DB >> 30285659 |
Emilio Rodríguez-Castro1,2, Iria López-Dequit1,2, María Santamaría-Cadavid1,2, Susana Arias-Rivas1,2, Manuel Rodríguez-Yáñez1,2, José Manuel Pumar1,3, Pablo Hervella1, Esteban López-Arias1, Andrés da Silva-Candal1, Ana Estany4, María Piñeiro-Lamas5, Tomás Sobrino1, Francisco Campos1, Manuel Portela1,6, Manuel Vázquez-Lima7, José Castillo8,9, Ramón Iglesias-Rey10,11.
Abstract
BACKGROUND: Studying the impact of demographic changes and progress in the management of stroke patients is necessary in order to organize care structures for the coming years. Consequently, we analyzed the prognostic trends of patients admitted to the Stroke Unit of a tertiary hospital in the last ten years.Entities:
Keywords: Intracerebral hemorrhage; Ischemic stroke; Morbidity; Mortality
Mesh:
Year: 2018 PMID: 30285659 PMCID: PMC6171303 DOI: 10.1186/s12883-018-1164-7
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Fig. 1Demographic data of the Health Area of Santiago de Compostela. [Instituto Galego de Estadística, 2016. Instituto Nacional de Estadística, 2016 (www.ige.eu)]
Fig. 2Demographic, clinical and progress characteristics of the sample analyzed: a Age pyramid of the sample analyzed by sex. b Trends in the distribution by age and sex. c Trends in intrahospital progress according to the reperfusion treatment. d Trends in the distribution by etiopathogenesis (ischemic stroke)
Fig. 3Trends of the factors that modify the risk of stroke: a Classic vascular risk factors. b Factors of heart disease, peripheral arterial disease and preventive drugs
Fig. 4Modified Rankin scale at 3 months: a Patients with ischemic stroke without reperfusion treatment. b Patients with ischemic stroke with reperfusion treatment
Multinomial logistic regression: Influence of the clinical, biochemical and neuroimaging variables on the outcome variables (morbidity and mortality) at 3 months from stroke onset
| Ischemic stroke | Intracerebral hemorrhage | |||||||
|---|---|---|---|---|---|---|---|---|
| Morbidity | Mortality | Morbidity | Mortality | |||||
| OR (95% CI)* |
| OR (95% CI)* |
| OR (95% CI)* |
| OR (95% CI)* |
| |
| WHOLE SAMPLE | ||||||||
| Age (year) | 1.03 (1.02–1.04) | < 0.001 | 1.06 (1.05–1.07) | < 0.001 | 1.01 (0.99–1.03) | 0.148 | 1.04 (1.02–1.06) | 0.001 |
| Stroke on awakening | 1.35 (1.06–1.72) | 0.014 | 1.57 (1.06–2.37) | 0.024 | ||||
| Maximum axillary temperature - first 24 h ( | 1.51 (1.33–1.71) | < 0.001 | 2.22 (1.06–2.37) | < 0.001 | 1.32 (0.97–1.79) | 0.076 | 1.92 (1.37–2.68) | < 0.001 |
| Baseline glycemia (mg/dL) | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 | ||||
| Fibrinogen (mg/dL) | 1.00 (1.00–1.00) | 0.019 | 1.00 (1.00–1.00) | 0.065 | ||||
| White blood cells (×103/mL) | 1.11 (1.09–1.14) | < 0.001 | 1.23 (1.19–1.28) | < 0.001 | ||||
| Baseline volume of hematoma (mL) | 1.03 (1.02–1.04) | < 0.001 | 1.05 (1.04–1.06) | < 0.001 | ||||
| PERIOD 2008–2011 | ||||||||
| Age (years) | 1.02 (0.99–1.05) | 0.079 | 1.05 (1.02–1.09) | 0.001 | ||||
| Maximum axillary temperature - first 24 h ( | 1.20 (0.86–1.64) | 0.280 | 2.37 (1.47–3.82) | < 0.001 | ||||
| Baseline glycemia (mg/dL) | 1.00 (1.00–1.00) | 0.001 | 1.00 (1.00–1.01) | 0.047 | ||||
| Fibrinogen (mg/dL) | 1.00 (1.00–1.00) | 0.043 | 1.00 (1.00–1.00) | 0.123 | ||||
| C-reactive protein (mg/L) | 1.11 (1.05–1.17) | < 0.001 | 1.22 (1.14–1.31) | < 0.001 | ||||
| TOAST: | ||||||||
| - Lacunar | 0.29 (0.13–0.64) | 0.002 | 1.14 (0.13–9.90) | 0.905 | ||||
| - Cardioembolic + Indeterminate | 1.32 (0.90–1.93) | 0.153 | 3.08 (1.48–6.40) | 0.003 | ||||
| - Atherothrombotic + Others | ref. | ref. | ||||||
| Ischemic injury volume in 2nd CT (mL) | 1.04 (1.03–1.05) | < 0.001 | 1.05 (1.04–1.06) | < 0.001 | ||||
| Baseline hematoma volume (mL) | 1.03 (1.01–1.05) | 0.001 | 1.08 (1.05–1.10) | < 0.001 | ||||
| PERIOD 2012–2017 | ||||||||
| Age (years) | 1.04 (1.03–1.05) | < 0.001 | 1.07 (1.05–1.09) | < 0.001 | 1.01 (0.97–1.04) | 0.679 | 1.05 (1.01–1.10) | 0.025 |
| Maximum axillary temperature - first 24 h ( | 1.12 (1.08–1.15) | < 0.001 | 1.24 (1.17–1.30) | < 0.001 | ||||
| Baseline glycemia (mg/dL) | 1.00 (1.00–1.00) | 0.019 | 1.00 (1.00–1.00) | < 0.001 | ||||
| Fibrinogen (mg/dL) | 1.00 (1.00–1.01) | 0.015 | 1.00 (0.99–1.00) | 0.177 | ||||
| White blood cells (×103/mL) | 1.12 (1.08–1.15) | < 0.001 | 1.24 (1.17–1.30) | < 0.001 | ||||
| Baseline hematoma volume (mL) | 1.03 (1.01–1.06) | 0.001 | 1.05 (1.03–1.07) | < 0.001 | ||||
| Edema volume in 2nd CT (mL) | 1.02 (0.98–1.05) | 0.290 | 1.04 (1.00–1.07) | 0.047 | ||||
*Adjusted OR. Good outcome was considered the reference category to calculate the ORs (CI 95%)
Fig. 5Modeling of time series for good outcome (mRS ≤ 2), morbidity (mRS > 2) and mortality (mRS = 6). The predictions at two years are presented in red, with their confidence intervals at 90% (dark gray) and 95% (light gray)